(Q33862078)

29 July 2017

title

Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium (English)

1 reference

29 July 2017

0 references

0 references

0 references

1 reference

United States of America

1 reference

3

Joseph Peuskens

1 reference

29 July 2017

Tim Lambert

1

1 reference

29 July 2017

José M Olivares

2

1 reference

29 July 2017

Cherilyn DeSouza

4

1 reference

29 July 2017

Chris M Kozma

5

1 reference

29 July 2017

Patrick Otten

6

1 reference

29 July 2017

Concetta Crivera

7

1 reference

29 July 2017

An Jacobs

8

1 reference

29 July 2017

Wayne Macfadden

9

1 reference

29 July 2017

Lian Mao

10

1 reference

29 July 2017

Stephen C Rodriguez

11

1 reference

29 July 2017

Riad Dirani

12

1 reference

29 July 2017

Kasem S Akhras

13

1 reference

29 July 2017

publication date

4 April 2011

1 reference

Annals of General Psychiatry

29 July 2017

published in

1 reference

29 July 2017

volume

10

1 reference

29 July 2017

page(s)

10

1 reference

Costs of treating patients with schizophrenia who have illness-related crisis events

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090384

Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090384

Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090384

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090384

Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090384

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090384

Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090384

Relapse and rehospitalization: comparing oral and depot antipsychotics.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090384

Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090384

Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090384

A comparison of observational studies and randomized, controlled trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090384

Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090384

Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia

5 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1744-859X-10-10

Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1744-859X-10-10

Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1744-859X-10-10

A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1744-859X-10-10

Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1744-859X-10-10

Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1744-859X-10-10

Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1744-859X-10-10

A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA)

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1744-859X-10-10

A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090384

Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090384

Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090384

Guidelines for depot antipsychotic treatment in schizophrenia

29 October 2018

1 reference

https://api.crossref.org/works/10.1186%2F1744-859X-10-10

21 January 2018

Identifiers

DOI

10.1186/1744-859X-10-10

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference

29 July 2017

1 reference